Kane Biotech Inc. (KNE.V)
CAD 0.1
(0.0%)
CAD 0.1
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 7.52 Million CAD | 47.95% |
| 2022 | 5.75 Million CAD | 61.49% |
| 2021 | 3.56 Million CAD | 186.78% |
| 2020 | 1.24 Million CAD | 286.96% |
| 2019 | -664.31 Thousand CAD | -256.47% |
| 2018 | 424.57 Thousand CAD | 121.49% |
| 2017 | -1.97 Million CAD | -661.15% |
| 2016 | -259.57 Thousand CAD | -180.53% |
| 2015 | 322.33 Thousand CAD | 162.27% |
| 2014 | -517.66 Thousand CAD | -134.03% |
| 2013 | -221.19 Thousand CAD | 84.37% |
| 2012 | -1.41 Million CAD | -7.25% |
| 2011 | -1.31 Million CAD | -603.59% |
| 2010 | -187.52 Thousand CAD | 76.7% |
| 2009 | -804.91 Thousand CAD | -46.62% |
| 2008 | -548.98 Thousand CAD | -59.35% |
| 2007 | -344.51 Thousand CAD | 50.03% |
| 2006 | -689.39 Thousand CAD | -80.47% |
| 2005 | -381.99 Thousand CAD | -38.39% |
| 2004 | -276.03 Thousand CAD | 66.52% |
| 2003 | -824.42 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 8.37 Million CAD | 11.21% |
| 2024 Q2 | 1.37 Million CAD | -83.56% |
| 2023 Q4 | 7.52 Million CAD | -0.56% |
| 2023 Q1 | 6.93 Million CAD | 20.63% |
| 2023 Q2 | 6.89 Million CAD | -0.55% |
| 2023 FY | 8.46 Million CAD | 47.12% |
| 2023 Q3 | 7.56 Million CAD | 9.7% |
| 2022 Q2 | 4.19 Million CAD | 5.08% |
| 2022 Q1 | 3.98 Million CAD | 12.0% |
| 2022 Q4 | 5.75 Million CAD | 4.79% |
| 2022 FY | 5.75 Million CAD | 61.49% |
| 2022 Q3 | 5.48 Million CAD | 30.95% |
| 2021 Q3 | 3.35 Million CAD | 10.05% |
| 2021 Q1 | 1.57 Million CAD | 26.77% |
| 2021 FY | 3.56 Million CAD | 186.78% |
| 2021 Q2 | 3.04 Million CAD | 93.7% |
| 2021 Q4 | 3.56 Million CAD | 6.12% |
| 2020 Q3 | -525.81 Thousand CAD | -276.21% |
| 2020 FY | 1.24 Million CAD | 286.96% |
| 2020 Q2 | 298.4 Thousand CAD | 350.06% |
| 2020 Q4 | 1.24 Million CAD | 336.2% |
| 2020 Q1 | -119.33 Thousand CAD | 82.04% |
| 2019 Q3 | 306.04 Thousand CAD | 136.91% |
| 2019 FY | -664.31 Thousand CAD | -256.47% |
| 2019 Q4 | -664.31 Thousand CAD | -317.06% |
| 2019 Q1 | 377.21 Thousand CAD | -11.16% |
| 2019 Q2 | -829.27 Thousand CAD | -319.84% |
| 2018 Q3 | 378.47 Thousand CAD | 210.61% |
| 2018 Q2 | -342.15 Thousand CAD | 72.51% |
| 2018 Q4 | 424.57 Thousand CAD | 12.18% |
| 2018 FY | 424.57 Thousand CAD | 121.49% |
| 2018 Q1 | -1.24 Million CAD | 36.99% |
| 2017 FY | -1.97 Million CAD | -661.15% |
| 2017 Q2 | 656.53 Thousand CAD | 849.29% |
| 2017 Q4 | -1.97 Million CAD | 21.82% |
| 2017 Q3 | -2.52 Million CAD | -484.94% |
| 2017 Q1 | -87.62 Thousand CAD | 66.24% |
| 2016 Q1 | 448.36 Thousand CAD | 39.1% |
| 2016 FY | -259.57 Thousand CAD | -180.53% |
| 2016 Q4 | -259.57 Thousand CAD | 71.65% |
| 2016 Q3 | -915.73 Thousand CAD | 41.17% |
| 2016 Q2 | -1.55 Million CAD | -447.19% |
| 2015 Q1 | -94.08 Thousand CAD | 81.83% |
| 2015 FY | 322.33 Thousand CAD | 162.27% |
| 2015 Q3 | 279.36 Thousand CAD | 22.72% |
| 2015 Q4 | 322.33 Thousand CAD | 15.38% |
| 2015 Q2 | 227.63 Thousand CAD | 341.95% |
| 2014 Q3 | 215 Thousand CAD | 1341.53% |
| 2014 FY | -517.66 Thousand CAD | -134.03% |
| 2014 Q1 | -387.07 Thousand CAD | -74.99% |
| 2014 Q2 | -17.31 Thousand CAD | 95.53% |
| 2014 Q4 | -517.66 Thousand CAD | -340.76% |
| 2013 Q1 | -1 Million CAD | 29.08% |
| 2013 Q4 | -221.19 Thousand CAD | 39.8% |
| 2013 Q2 | -672.36 Thousand CAD | 33.0% |
| 2013 FY | -221.19 Thousand CAD | 84.37% |
| 2013 Q3 | -367.45 Thousand CAD | 45.35% |
| 2012 Q4 | -1.41 Million CAD | -243.08% |
| 2012 FY | -1.41 Million CAD | -7.25% |
| 2012 Q1 | -963.54 Thousand CAD | 26.97% |
| 2012 Q2 | -728.85 Thousand CAD | 24.36% |
| 2012 Q3 | -412.44 Thousand CAD | 43.41% |
| 2011 Q1 | -96.1 Thousand CAD | 48.75% |
| 2011 FY | -1.31 Million CAD | -603.59% |
| 2011 Q2 | -1.9 Million CAD | -1880.81% |
| 2011 Q3 | -1.61 Million CAD | 15.23% |
| 2011 Q4 | -1.31 Million CAD | 18.24% |
| 2010 Q4 | -187.52 Thousand CAD | -13.17% |
| 2010 FY | -187.52 Thousand CAD | 76.7% |
| 2010 Q3 | -165.69 Thousand CAD | 60.54% |
| 2010 Q2 | -419.95 Thousand CAD | 26.1% |
| 2010 Q1 | -568.25 Thousand CAD | 29.4% |
| 2009 Q1 | -351.23 Thousand CAD | 36.02% |
| 2009 FY | -804.91 Thousand CAD | -46.62% |
| 2009 Q4 | -804.91 Thousand CAD | -188.51% |
| 2009 Q3 | -278.99 Thousand CAD | 16.31% |
| 2009 Q2 | -333.37 Thousand CAD | 5.09% |
| 2008 FY | -548.98 Thousand CAD | -59.35% |
| 2008 Q4 | -548.98 Thousand CAD | 17.96% |
| 2008 Q3 | -669.17 Thousand CAD | 43.13% |
| 2008 Q1 | -1.5 Million CAD | -335.58% |
| 2008 Q2 | -1.17 Million CAD | 21.59% |
| 2007 Q4 | -344.51 Thousand CAD | 37.26% |
| 2007 Q2 | -237.92 Thousand CAD | 50.13% |
| 2007 Q1 | -477.08 Thousand CAD | 30.8% |
| 2007 FY | -344.51 Thousand CAD | 50.03% |
| 2007 Q3 | -549.11 Thousand CAD | -130.79% |
| 2006 Q3 | -980.88 Thousand CAD | 20.32% |
| 2006 Q4 | -689.39 Thousand CAD | 29.72% |
| 2006 Q2 | -1.23 Million CAD | -568.06% |
| 2006 Q1 | -184.28 Thousand CAD | 51.76% |
| 2006 FY | -689.39 Thousand CAD | -80.47% |
| 2005 Q2 | -809.6 Thousand CAD | 27.82% |
| 2005 FY | -381.99 Thousand CAD | -38.39% |
| 2005 Q1 | -1.12 Million CAD | -306.35% |
| 2005 Q3 | -575.34 Thousand CAD | 28.94% |
| 2005 Q4 | -381.99 Thousand CAD | 33.61% |
| 2004 FY | -276.03 Thousand CAD | 66.52% |
| 2004 Q1 | -719.11 Thousand CAD | 12.77% |
| 2004 Q2 | -549.48 Thousand CAD | 23.59% |
| 2004 Q3 | -396.83 Thousand CAD | 27.78% |
| 2004 Q4 | -276.03 Thousand CAD | 30.44% |
| 2003 Q2 | -817.91 Thousand CAD | 0.0% |
| 2003 Q3 | -857.35 Thousand CAD | -4.82% |
| 2003 Q4 | -824.42 Thousand CAD | 3.84% |
| 2003 FY | -824.42 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Arch Biopartners Inc. | 4.18 Million CAD | -79.854% |
| Covalon Technologies Ltd. | -7.23 Million CAD | 204.073% |
| Hemostemix Inc. | 4.16 Million CAD | -80.666% |
| Universal Ibogaine Inc. | 1.01 Million CAD | -644.022% |
| MedMira Inc. | 9.25 Million CAD | 18.701% |
| Marvel Biosciences Corp. | 443.37 Thousand CAD | -1597.586% |
| NervGen Pharma Corp. | -11.46 Million CAD | 165.665% |
| XORTX Therapeutics Inc. | -4.53 Million CAD | 266.119% |